Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 676 across all filing types
Latest filing 2026-03-13 Investor Presentation
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 85% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about investor relations activities. The content is about informing the schedule of meetings (Non-Deal Roadshows) and does not contain any financial data, earnings, or detailed presentations. It is an announcement related to investor relations but not a full investor presentation or financial report. Given the nature of the document as an update on investor meetings, the most appropriate classification is Investor Presentation (IP), as it relates to investor communication and meetings, although it is a schedule notice rather than a full presentation. The document length is short (1772 characters), and it is not a report publication announcement or regulatory filing. Confidence is high due to clear context and content.
2026-03-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which mandates disclosure of material events. The content is a notification of upcoming meetings rather than a financial report, earnings release, or presentation. The document length is short (1666 characters) and does not contain financial data or detailed presentations. It is an announcement of scheduled meetings with investors and analysts, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-03-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 85% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides dates and types of meetings planned. There is no financial data, no report attached or referenced as being published, and no indication of a report or earnings release. The content is an announcement of upcoming investor relations activities, specifically analyst/investor meetings. This fits best under Investor Presentation (IP) as it relates to investor engagement and presentations, although it is a schedule notice rather than a full presentation document. Given the nature of the content, the closest classification is Investor Presentation (IP).
2026-03-09 English
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding a tax demand order received from the GST Authority for the fiscal year 2019-20. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events. The content includes details of the tax demand, penalties, and the company's intention to appeal. There are no financial statements, earnings data, or detailed management analysis. The document is a regulatory disclosure about a legal/tax matter, not a full audit report, annual report, or earnings release. It fits the category of Regulatory Filings (RNS) as it is a compliance disclosure under SEBI regulations about a material event affecting the company.
2026-03-06 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Gland Pharma has received tentative approval from the USFDA for a specific ophthalmic solution product. It is addressed to stock exchanges and references regulatory compliance under SEBI Listing Obligations. The content is an announcement of a regulatory milestone related to product approval, not a financial report, earnings release, or detailed investor presentation. The document length is 3751 characters, which is relatively short and typical for a press release. There is no financial data, no meeting materials, no voting results, no management discussion, and no audit or legal information. The document is best classified as a Regulatory Filings (RNS) type, which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2026-03-04 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in key management personnel, specifically the resignation of the CEO. It references compliance with SEBI regulations about disclosure of such changes. The content includes details about the resignation date and related annexures but does not contain financial data, earnings, or report content. The document is clearly an announcement of management change rather than a financial report or other filing type.
2026-03-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.